Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization

Tumas, Daniel B.; Chan, Betty; Werther, Winifred R.; Wrin, Terri; Vennari, Joann; Desjardin, Noelyn; Shields, Robert L.; Jardieu, Paula

doi:10.1067/mai.2001.115625

Cited by 46 publications

(29 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histologically, anti-IgE antibody also significantly reduces infiltration of PMNLs and eosinophils into the dermis of TMA-challenged Balb/c mice. Our data are in agree with revious reports, which show that IgE plays a critical role in the production of Th2 cytokienes in the development of eosinophil recruitment into the inflammation site after antigen provocation and the initial development of the late allergic responses (Haile et al, 1999;Tumas et al, 2001;Yokozeki et al, 2003;Coyle et al, 2005).…”

Section: Discussionsupporting

confidence: 70%

“…Increased production of IgE in response to common environmental antigens is the hallmark of allergic diseases such as bronchial asthma, allergic rhinitis, and atopic dermatitis (Burr, 1993). Some studies showed the roles of IgE in the development of allergic inflammation, airway hyprresponsiveness, and contact hypersensitivity in a murine model (Haile et al, 1999;Tumas et al, 2001;Yokozeki et al, 2003;Coyle et al, 2005). However, the detailed role of IgE remains to be characterized.…”

Section: Roles Of Tnf-α and Ige In The Late Phase Of Contact Hypersenmentioning

confidence: 99%

See 1 more Smart Citation

Roles of TNF-α and IgE in the late phase of contact hypersensitivity induced by trimellitic anhydride

Chai

Lee²,

Lee³

et al. 2005

Exp Mol Med

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Roles Of Tnf-α and Ige In The Late Phase Of Contact Hypersenmentioning

confidence: 99%

Roles of TNF-α and IgE in the late phase of contact hypersensitivity induced by trimellitic anhydride

Chai

Lee²,

Lee³

et al. 2005

Exp Mol Med

View full text Add to dashboard Cite

show abstract

“…In murine asthma models, it has clearly been demonstrated that anti-IgE monoclonal antibody (mAb) depletes IgE and significantly reduces lung eosinophilic inflammation [12]. The humanized murine monoclonal antibody to IgE, rhumAb-E25 (Omalizumab) recognizes the specific Fce3 portion of circulating IgE that binds to the high-affinity IgEreceptor.…”

Section: Ige As a Targetmentioning

confidence: 99%

Asthma therapy in the new millennium

Pahl¹,

Szelenyi²

2002

Inflamm. res.

View full text Add to dashboard Cite

Bronchial asthma is one of the most common chronic diseases in modern society and yet, despite the availability of highly effective drugs, there is increasing evidence to suggest that its incidence is increasing. It is a general health problem in several industrialised countries and will remain one for the next decades. With regard to asthma pathogenesis, our understanding has increased tremendously over the last two decades. Therefore, the potential for specific targeted and constructed therapies has become evident. Monoclonal antibodies to IgE, soluble receptors or antibodies to certain cytokines such as IL-4 and IL-5 are being investigated as possible treatments for asthma. Besides the already known receptor antagonists, new compounds directed to novel receptor types (e.g. cytokine, adenosine, adhesion molecules, etc.) are now under development. New targets in the cytosol will come into focus. Preliminary studies of selective phosphodiesterase (PDE) inhibitors in asthmatic patients have been encouraging. It is also very likely that the use of glucocorticoids cannot be excluded from therapy. However, we should generate new glucocorticoids with less side-effects, probably by using the so-called retrometabolic drug design. The first representative of this new steroid class, loteprednol is already approved for the therapy of certain allergic disorders. Because asthma is a disease of many different gene polymorphisms, gene therapy seems to be of low success at present. Alternatively, antisense oligonucleotides could be used. Future developments may also include strategies targeting the remodeling of structural elements of the airways. Today's intensive search for new treatments should ensure a greater diversity of therapeutic possibilities for the management of asthma in the next millennium.

show abstract

“…Sensitization to antigen in these models is typically carried out using an intraperitoneal route of immunization. In a murine system that attempted to mimic human asthma by sensitization with aerosolized allergen, administration of anti-IgE was associated with decreased lung eosinophilic inflammation and airway mucosa pathology [12]. These observations point to a pivotal role for IgE Ab in the development of lung eosinophilia.…”

Section: Introductionmentioning

confidence: 96%

A new paradigm for Immunoglobulin E in allergic diseases

Woodfolk

2005

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Recent observations at the level of the antigen presenting cell, as well as the T cell, point toward a pivotal role for interleukin (IL)-10 in the control of immunoglobulin E (IgE)-mediated allergic diseases, such as asthma and rhinitis. This has led to restructuring of the Th1/Th2 paradigm with IL-10 acting to modulate Th2-driven IgE antibody (Ab) responses. The modified Th2 response to cat allergen is associated with high-dose allergen exposure and the presence of high titer IgG and IgG4 Ab; however, IgE Ab and allergic symptoms are absent. Characteristics of this immune response indicate that it is a variant of the allergic response, which develops in an IL-10-dependent manner, but it is distinct from other types of nonallergic or tolerant responses. These observations point toward a new paradigm for the development of IgE-mediated responses. This may be important for advancing our understanding of the response to immunotherapy and anti-IgE, and for defining immune mechanisms that drive allergic responses.

show abstract

Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization

Cited by 46 publications

References 59 publications

Roles of TNF-α and IgE in the late phase of contact hypersensitivity induced by trimellitic anhydride

Roles of TNF-α and IgE in the late phase of contact hypersensitivity induced by trimellitic anhydride

Asthma therapy in the new millennium

A new paradigm for Immunoglobulin E in allergic diseases

Contact Info

Product

Resources

About